NCT04082390Unknown不适用
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effects of the GOLO for Life System Diet With and Without GOLO Release Supplement on Glycemic Control and Insulin Resistance in Overweight and Obese Subjects With Type 2 Diabetes
Golo0 个研究点目标入组 36 人开始时间: 2019年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 36
- 主要终点
- Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement
研究概览
简要总结
This randomized, double-blind placebo-controlled study is intended to observe the short-term effects of the GFL System Diet with Release supplement versus GFL System Diet with placebo on glycemic metabolism and insulin resistance in patients with Type 2 DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years and ≤ 80 years
- •Body mass index (BMI) ≥ 27 and ≤ 60 kg/m2
- •Have the ability to engage in at least 15 minutes of moderate physical activity such as brisk walking
- •A1C greater than or equal to 6.5% at screening
- •Willing to comply with study procedures described herein
排除标准
- •Current diagnosis of type 1 diabetes
- •Subjects with a history of hypoglycemia
- •A history of an eating disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- •Known allergy to any of the components in the Release supplement
- •A history of prior surgery for weight loss within one year from screening
- •Currently taking injectable medications to control diabetes, including insulin and GLP-1 agonists
- •Currently pregnant or breastfeeding or have had a baby within the last six weeks
- •Planning to become pregnant in the next three months. Women of child-bearing potential must be willing and able to use adequate and reliable contraception throughout the study (e.g. abstinence or barrier with additional spermicidal foam or jelly, or the use of intrauterine device or hormonal contraception).
- •Uncontrolled hypertension at screening defined as Systolic blood pressure greater than 180 mmHG or Diastolic blood pressure greater than 110 mmHG
- •Current clinical diagnosis or signs and symptoms of unstable (in the opinion of the principle investigator) heart, kidney or liver disease, cancer, or chronic neurological disease.
- •Current participation in any other weight loss or weight management program
- •Currently taking weight loss medications, or medications or supplements known to be associated with significant weight loss or weight gain
- •Has any condition that, in the opinion of the investigator, would make participation in this study not in the best interest of the subject or that could prevent, limit or confound the protocol-specified assessments. Examples include: history of diabetic ketoacidosis; active chronic liver disease or cirrhosis; chronic autoimmune disease; inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, subjects predisposed to intestinal obstruction; chronic intestinal diseases associated with marked disorders of digestion or absorption
结局指标
主要结局
Change in Fasting Blood Glucose (FBG) at approximately 4 weeks of the GFL System Diet with Release supplement versus GFL System Diet with placebo supplement
时间窗: 4 weeks
次要结局
- Change from baseline in Weight between the 2 groups(4 weeks)
- Change from baseline in HGB A1C between the 2 groups(4 weeks)
- Change from baseline in HOMA-IR between the 2 groups(4 weeks)
- Change from baseline in Body Mass Index between the 2 groups(4 weeks)
- Change from baseline in Waist Circumference between the 2 groups(4 weeks)
- Change from baseline in Insulin Levels between the 2 groups(4 weeks)
- Change from baseline in Blood Pressure between the 2 groups(4 weeks)
- Change from baseline in Fructosamine between the 2 groups(4 weeks)
- Change from baseline in Hip Circumference between the 2 groups(4 weeks)
- Change from baseline in Heart Rate between the 2 groups(4 weeks)
研究者
相似试验
进行中（未招募）
2 期
Study of Suramin in Subjects With Furosemide-Resistant AKIAcute Kidney InjuryNCT04496596Rediscovery Life Sciences68
Unknown
不适用
The Effects of Gut Micribiota Disruption on the Immune Response After Open Heart SurgeryPostoperative ShockSystemic Inflammatory Response SyndromeCoronary Artery DiseaseExtracorporeal Circulation ComplicationsNCT03939273Radboud University Medical Center80
撤回
4 期
Placebo-controlled Trial With Nasonex for Nasal Obstruction Secondary to Adenoids Hypertrophy in Children (P04367)(TERMINATED)Nasal ObstructionAdenoids HypertrophyAdenoidectomyNCT00553891Organon and Co
已完成
2 期
Phase 2 Study of KHK4577Atopic DermatitisNCT02004119Kyowa Kirin Co., Ltd.93
已完成
不适用
Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD PatientsNon Alcoholic Fatty LiverNCT02923804Pronova BioPharma172